Related Experiment Video

Updated: Dec 8, 2025

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.5K

Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment

James A Seddon1,2, Sarah Johnson1,2, Megan Palmer1

  • 1Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University , Stellenbosch, South Africa.

Expert Review of Respiratory Medicine
|September 23, 2020
PubMed

Insights

Multidrug-resistant tuberculosis (TB) in children is underdiagnosed and undertreated. Advances in diagnostics and treatments offer improved pediatric care, but more research and implementation are crucial for better outcomes.

Area of Science:

  • Pediatric infectious diseases
  • Mycobacterial infections
  • Global child health

Background:

  • An estimated 30,000 children annually develop multidrug-resistant tuberculosis (MDR-TB).
  • Pediatric MDR-TB management has been historically neglected due to diagnostic and treatment challenges.
  • Recent advancements in adult TB care are improving pediatric approaches, yet pediatric-specific research is needed.

Purpose of the Study:

  • To review best practices for evaluating, diagnosing, treating, and supporting children with MDR-TB.
  • To provide practical guidance on MDR-TB prevention and updates on novel treatment regimens.
  • To address host-directed therapy, comorbidities, special populations, psychosocial support, and research gaps.

Main Methods:

  • Comprehensive literature search of PubMed for pediatric MDR-TB topics.
  • Synthesis of recent data and expert opinion.
  • Review of diagnostic and therapeutic developments, including novel agents and repurposed drugs.

Main Results:

  • Molecular diagnostics show promise for improving pediatric MDR-TB diagnosis.
  • Shorter MDR-TB treatment regimens enhance safety and reduce duration.
  • Growing evidence supports MDR-TB preventive therapy in children.

Conclusions:

  • Continued research and implementation of evidence-based practices are essential for pediatric MDR-TB.
  • Novel treatments and improved diagnostics are enhancing therapeutic options.
  • A holistic approach including psychosocial support and management of comorbidities is vital.
Abstract

Keywords:
Tuberculosischildrenmultidrug-resistantpediatricpreventionresistanttreatment

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.2K

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
356
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
580
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
312
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
632
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108